Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain fog after COVID: can two common drugs clear it?

NCT ID NCT07722000

Symptom relief Sponsor: Beni-Suef University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This trial investigates whether ginkgo biloba, piracetam, or a combination of both can help people recover from persistent symptoms after COVID-19, such as memory problems and fatigue. The study enrolls adults aged 18 to 70 who had COVID-19 within the past three months. Participants receive one of the treatments, and researchers track changes in cognitive function and fatigue levels over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ginkgo biloba and/or piracetam
What this could lead to
If effective, these treatments could offer a simple, widely available option for managing post-COVID cognitive and fatigue symptoms.
What could go wrong
This is a small, early-stage trial with no placebo group, so results may be inconclusive. Ginkgo biloba and piracetam are generally safe but can cause side effects like headache or dizziness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

90 people

The number who actually took part.

Started

Feb 2021

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged from 18 to 70 years. * Both sexes. * Positive diagnosis of COVID-19 within the last 3 months in relation to the time of assessment (COVID-19 diagnosis had been previously confirmed by RT-PCR nasal swab testing as part of routine clinical evaluation before enrollment into the study). Exclusion Criteria: * Patients with other non-COVID-related chronic illnesses that could interfere with the assessment of post-viral symptoms. * Patients with pre-existing neurological disorders that could affect cognitive function or fatigue assessment, including dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, or prior cerebrovascular stroke, patients with diagnosed psychiatric disorders such as major depressive disorder, bipolar disorder, schizophrenia, or anxiety disorders requiring ongoing pharmacological treatment. * Patients with uncontrolled endocrine disorders, particularly uncontrolled diabetes mellitus or thyroid dysfunction. * Patients with malignancy or receiving chemotherapy, radiotherapy, or immunosuppressive therapy during the study period. * Patients with chronic fatigue syndrome, fibromyalgia, or other pre-existing fatigue-related disorders diagnosed prior to SARS-CoV-2 infection. * Patients with substance abuse or alcohol dependence, pregnant or lactating women. * Patients with known hypersensitivity or contraindications to Ginkgo biloba or piracetam. * Patients with poor adherence to treatment or anticipated inability to complete follow-up visits.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 long COVID-19 post-COVID-19 disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 Ginkgo biloba Piracetam Post-COVID-19 syndrome

Contacts and locations

Locations

  • Beni Suef University

    Banī Suwayf, Beni Suweif Governorate, 62511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.